DelveInsight has launched a new report on Amyotrophic Lateral Sclerosis Market
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body.
Request for free sample copy- https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market
The Amyotrophic Lateral Sclerosis market report provides an edge while developing business strategies, by understanding trends shaping and driving the Amyotrophic Lateral Sclerosis (ALS) market.
Amyotrophic Lateral Sclerosis Treatment
There is no cure and no proven treatment for ALS. However, available treatments can help control symptoms, prevent unnecessary complications, and make the patient’s life easier. The disease progresses over 3–5 years, making voluntary movements of arms and legs impossible. In time, the patient will need help with personal care, eating, and mobility.
Movement of the diaphragm for breathing is also impaired, and the patient may need a ventilator for breathing. Most people with ALS die from respiratory failure. For most people with ALS, the main treatment may involve the management of symptoms. Supportive care is best provided by multidisciplinary teams of healthcare professionals such as physicians, pharmacists, therapists—physical, occupational, and speech—nutritionists, social workers, respiratory therapists, clinical psychologists, and home care and hospice nurses.
Key player of the Amyotrophic Lateral Sclerosis Market Report
Amyotrophic Lateral Sclerosis Treatment Market
Currently, there is no cure for ALS and no effective treatment to halt or reverse, the progression of the disease. The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counselling, heat or whirlpool therapy and others. Moreover, there are four drugs approved by the US FDA to treat ALS, namely Riluzole, Nuedexta, Radicava, and Tiglutik. Medications are also prescribed to help manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs also are available to help individuals with pain, depression, sleep disturbances, and constipation.
Amyotrophic Lateral Sclerosis Market Disease
Nuedexta is a combination drug containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of pseudobulbar affect (PBADextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases dextromethorphan plasma levels by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown
Amyotrophic Lateral Sclerosis Drugs
Amyotrophic Lateral Sclerosis Market Report Scope
Table of content
1. Key Insights
2. Executive Summary of Amyotrophic lateral sclerosis (ALS)
3. Competitive Intelligence Analysis for Amyotrophic lateral sclerosis (ALS)
4. Amyotrophic lateral sclerosis (ALS): Market Overview at a Glance
5. Amyotrophic lateral sclerosis (ALS): Disease Background and Overview
6. Patient Journey
7. Amyotrophic lateral sclerosis (ALS) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Amyotrophic lateral sclerosis (ALS) Treatment
11. Marketed Products
12. Emerging Therapies
13. Amyotrophic lateral sclerosis (ALS): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Amyotrophic lateral sclerosis (ALS)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Reasons to buy
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 Country: United StatesWebsite: www.delveinsight.com/
